a 2021 0066

The invention relates to chemistry and medi-cine, in particular to the use of a biologically active copper coordination compound of the class of transition metal thiosemicarbazonates as a synthetic growth factor inhibitor. This complex can find application in medicine as a preparation, which, by inhibiting the excessive production of growth factors in the organism, prevents the development of cell and tissue injuries, related to excessive accumulation of connective tissue, inflammatory processes, neurodegenerative, renal, cardiovascular pa-thologies, atherosclerosis and carcinogenesis.

Summary of the invention consists in the use of chloro-{N-ethyl-N'-[phenyl(pyridin-2-yl)me-thylidene]carbamohydrazonethioato}copper with the formula:



as an inhibitor of growth factors selected from the group consisting of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor-beta (FGF-β) and transforming growth factor-beta (TGF-β).

The said compound expands the arsenal of growth factor inhibitors with high biological activity.

Claims: 1